Sargent Bickham Lagudis’s DermTech, Inc. Common Stock DMTK Stock Holding History

Sargent Bickham Lagudis’s Portfolio DMTK Stock Details DMTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-4,482	Closed	-$18K	–	1096
2022 Q3	$18K	Hold	4,482	–	–	﹤0.01%	598
2022 Q2	$25K	Hold	4,482	–	–	﹤0.01%	550
2022 Q1	$66K	Hold	4,482	–	–	0.01%	399
2021 Q4	$71K	Hold	4,482	–	–	0.01%	395
2021 Q3	$144K	Hold	4,482	–	–	0.01%	285
2021 Q2	$186K	Buy	+4,482	New	+$184K	0.02%	266

Other funds holding DMTK

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Luther King Capital Management (LKCM) Fort Worth, Texas $23.1B AUM 21.31% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EPIQ Partners Minneapolis, Minnesota $236M AUM 15.39% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

WPC

White Pine Capital Bloomington, Minnesota $355M AUM 45.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sargent Bickham Lagudis's DMTK Position: Q4 2022 in Review

Sargent Bickham Lagudis sold out of DermTech, Inc. Common Stock (DMTK) in Q4 2022, closing a stake of 4,482 shares — an estimated $18K sold.

Sargent Bickham Lagudis first reported a position in DMTK in Q2 2021 and held it in 6 quarters. The position peaked at $186K in Q2 2021. 94 funds tracked by Wall St. Rank hold DMTK as of Q4 2022.

Sargent Bickham Lagudis reported no remaining DermTech, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Sargent Bickham Lagudis sold 4,482 DermTech, Inc. Common Stock shares in Q4 2022, an estimated $18K.
Sargent Bickham Lagudis first reported a position in DermTech, Inc. Common Stock in Q2 2021 and held it in 6 quarters.
Sargent Bickham Lagudis's DermTech, Inc. Common Stock position peaked at $186K in Q2 2021.
94 funds tracked by Wall St. Rank held DermTech, Inc. Common Stock as of Q4 2022.

Based on Sargent Bickham Lagudis's 13F filing for Q4 2022, filed 23 Jan 2023.